Biologics Market - Global Forecast 2026-2032

The biologics market is experiencing strong momentum, with industry executives navigating rapid scientific progress, evolving regulations, and new commercial imperatives. Forward-thinking leaders are responding by aligning research innovation, manufacturing capabilities, and patient-focused delivery models to meet shifting stakeholder demands.

Market Snapshot: Biologics Market

The Biologics Market grew from USD 459.45 billion in 2025 to USD 486.37 billion in 2026. It is expected to continue growing at a CAGR of 6.61%, reaching USD 719.17 billion by 2032. This robust expansion reflects increasing adoption of advanced therapies, diversification of end-user segments, and the emergence of new technology platforms supporting efficient development and delivery.

Scope & Segmentation

Product Types: Blood factor products, cell therapies (including CAR-T and stem cell modalities), gene therapies, monoclonal antibodies, recombinant proteins, vaccines
Enabling Technologies: Cell culture innovations, recombinant DNA, hybridoma techniques, gene editing platforms (CRISPR, TALENs, zinc finger nucleases), digital bioprocess controls
Route of Administration: Intramuscular, intravenous, subcutaneous
Therapeutic Indications: Autoimmune, cardiovascular, infectious diseases, metabolic, neurological, oncology
End Users: Hospitals, clinics, home healthcare, research institutes
Distribution Channels: Hospital pharmacies, retail and online pharmacies, specialty distribution networks
Regional Coverage: Americas, Europe-Middle East-Africa, Asia-Pacific

Key Takeaways

Scientific breakthroughs in gene editing and cell therapy are expanding possible indications and personalizing treatment pathways for a broader patient base.
Operational strategies are shifting towards integration, requiring coordination across research, process development, and commercial teams for efficient innovation delivery.
Manufacturers are responding to heightened demands for flexibility by adopting platform technologies and digital bioprocess systems to maintain quality and scalability.
Payers and providers increasingly require real-world evidence tied to long-term outcomes, changing how sponsors approach evidence generation and reimbursement planning.
End-user and distribution segmentation shapes workflow, product format choices, and patient access, prompting tailored go-to-market strategies across regions and settings.
Workforce development is crucial as companies emphasize GMP operations, digital systems, and regulatory understanding for complex biologic modalities.

Tariff Impact on Biologics Value Chains

Recent tariff changes and trade policy adjustments are directly impacting sourcing, regional manufacturing, and partnership models. Leaders are reevaluating supplier diversification and accelerating the qualification of new vendors to reduce operational risks tied to imported reagents or equipment. The strategic shift toward regionalizing production—especially for critical manufacturing steps—seeks to minimize trade-related delays and ensure consistent supply. In licensing and partnership negotiations, organizations are increasingly considering technology transfer or joint ventures as levers for market access and quality control. Supply-chain scenario planning and contractual flexibility are essential to sustain development and commercialization despite evolving policies.

Methodology & Data Sources

Analysis integrates senior leadership interviews across development, manufacturing, regulatory, and commercial functions. These are complemented by secondary research including scientific literature, regulatory documentation, and conference data. Triangulation and scenario analysis ensure operational, technological, and regional insights reflect validated industry consensus.

Why This Report Matters

Enables executives to benchmark strategies for integrating scientific innovation with operational execution in the biologics sector.
Supports planning with actionable segmentation frameworks tailored to product modality, technology adoption, and regional footprint.
Helps leaders anticipate and adapt to policy, regulatory, and supply-chain changes shaping future competitiveness and patient access.

Conclusion

Sustained biologics success relies on harmonizing innovation and operational excellence. Leaders who embrace segmentation, invest in workforce readiness, and foster resilient ecosystem partnerships will shape the next phase of patient-centered biologics.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Market, by Product Type

8.1. Blood Factor Products
8.2. Cell Therapies
8.2.1. CAR-T Therapies
8.2.2. Stem Cell Therapy
8.3. Gene Therapies
8.4. Monoclonal Antibodies
8.5. Recombinant Proteins
8.6. Vaccines

9. Biologics Market, by Technology

9.1. Cell Culture Technology
9.2. Gene Editing Technology
9.2.1. CRISPR
9.2.2. TALENs
9.2.3. Zinc Finger Nucleases
9.3. Hybridoma Technology
9.4. Recombinant DNA Technology

10. Biologics Market, by Route Of Administration

10.1. Intramuscular
10.2. Intravenous
10.3. Subcutaneous

11. Biologics Market, by Therapeutic Area

11.1. Autoimmune
11.2. Cardiovascular Diseases
11.3. Infectious Diseases
11.4. Metabolic Disorders
11.5. Neurological Disorders
11.6. Oncology

12. Biologics Market, by End User

12.1. Clinics
12.2. Home Healthcare
12.3. Hospitals
12.4. Research Institutes

13. Biologics Market, by Distribution Channel

13.1. Hospital Pharmacy
13.2. Online Channel
13.3. Retail Pharmacy

14. Biologics Market, by Region

14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific

15. Biologics Market, by Group

15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO

16. Biologics Market, by Country

16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea

17. United States Biologics Market
18. China Biologics Market

19. Competitive Landscape

19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. Amgen Inc.
19.7. AstraZeneca PLC
19.8. Bayer AG
19.9. Biogen Inc.
19.10. Boehringer Ingelheim International GmbH
19.11. Bristol-Myers Squibb Company
19.12. Catalent Inc.
19.13. Celltrion Inc.
19.14. CSL Limited
19.15. Eli Lilly and Company
19.16. Gilead Sciences Inc.
19.17. GlaxoSmithKline plc
19.18. Johnson & Johnson
19.19. Lonza Group AG
19.20. Merck & Co. Inc.
19.21. Moderna Inc.
19.22. Novartis AG
19.23. Novo Nordisk A/S
19.24. Pfizer Inc.
19.25. Roche Holding AG
19.26. Samsung Biologics Co. Ltd.
19.27. Sanofi SA
19.28. Takeda Pharmaceutical Company Limited

List of Figures

FIGURE 1. GLOBAL BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY BLOOD FACTOR PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL BIOLOGICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BIOLOGICS MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL BIOLOGICS MARKET SIZE, BY TALENS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BIOLOGICS MARKET SIZE, BY ZINC FINGER NUCLEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BIOLOGICS MARKET SIZE, BY HYBRIDOMA TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL BIOLOGICS MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL BIOLOGICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BIOLOGICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL BIOLOGICS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BIOLOGICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BIOLOGICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL BIOLOGICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL BIOLOGICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL BIOLOGICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL BIOLOGICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL BIOLOGICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL BIOLOGICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL BIOLOGICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL BIOLOGICS MARKET SIZE, BY ONLINE CHANNEL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL BIOLOGICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. EUROPE BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. EUROPE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 142. EUROPE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 143. EUROPE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 144. EUROPE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 145. EUROPE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 146. EUROPE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 147. EUROPE BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. EUROPE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. AFRICA BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 160. AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 161. AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 162. AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 163. AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 165. AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 177. ASEAN BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. ASEAN BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 179. ASEAN BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 180. ASEAN BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 181. ASEAN BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 182. ASEAN BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183. ASEAN BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 184. ASEAN BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. ASEAN BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. GCC BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. GCC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 188. GCC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 189. GCC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 190. GCC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 191. GCC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. GCC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 193. GCC BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. GCC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. BRICS BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. BRICS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 206. BRICS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 207. BRICS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 208. BRICS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 209. BRICS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 210. BRICS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 211. BRICS BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. BRICS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 213. G7 BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. G7 BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 215. G7 BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 216. G7 BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 217. G7 BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 218. G7 BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 219. G7 BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 220. G7 BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. G7 BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. NATO BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. NATO BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 224. NATO BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 225. NATO BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 226. NATO BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 227. NATO BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. NATO BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 229. NATO BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. NATO BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 239. UNITED STATES BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 240. UNITED STATES BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 241. CHINA BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 242. CHINA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 243. CHINA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 244. CHINA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 245. CHINA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 246. CHINA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247. CHINA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 248. CHINA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 249. CHINA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Biologics market report include:

AbbVie Inc.
Amgen Inc.
AstraZeneca PLC
Bayer AG
Biogen Inc.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Catalent Inc.
Celltrion Inc.
CSL Limited
Eli Lilly and Company
Gilead Sciences Inc.
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group AG
Merck & Co. Inc.
Moderna Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Roche Holding AG
Samsung Biologics Co. Ltd.
Sanofi SA
Takeda Pharmaceutical Company Limited

Table Information

Report Attribute	Details
No. of Pages	199
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 486.37 Billion
Forecasted Market Value ( USD ) by 2032	$ 719.17 Billion
Compound Annual Growth Rate	6.6%
Regions Covered	Global
No. of Companies Mentioned	25

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3471EUR$3,939USD£3,022GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3745EUR$4,249USD£3,259GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5075EUR$5,759USD£4,418GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6142EUR$6,969USD£5,346GBP

Market Snapshot: Biologics Market

Scope & Segmentation

Key Takeaways

Tariff Impact on Biologics Value Chains

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Biologics Drug Discovery Market - A Global and Regional Analysis: Focus on Method, Manufacturing Type, Type, and Region, 2025-2035

Cancer Biologics Market - Global Forecast 2026-2032

Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing, and Region, 2025-2033

Biologics Market Report and Forecast 2025-2034

Biologics Contract Development Market - Global Forecast 2026-2032